Rhodia intents to sell its pharmaceutical custom synthesis busines to Shasun Chemicals & Drugs

09-Jan-2006

Rhodia announced the signature of a letter of intent with Shasun chemicals & Drugs Ltd with a view to selling its pharmaceutical custom synthesis business.

Jean-Pierre Clamadieu, Chief Executive Officer of Rhodia, said: "This transaction is in line with our announced strategy to refocus the Group's business portfolio and to find a solution for RPS (Rhodia Pharma Solutions). The transfer to Shasun will allow these activities to be pursued under optimum conditions for our customers."

Rhodia expects the transaction to be completed by the end of the 1st quarter of 2006, with the signature of the final contract, as well as the necessary official authorizations.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!